Endoscopy 2017; 49(10): 941-948
DOI: 10.1055/s-0043-112492
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Exploring diagnostic and therapeutic implications of endoscopic mucosal resection in EUS-staged T2 esophageal adenocarcinoma

Annieke W. Gotink
1   Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Manon C. W. Spaander
1   Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Michael Doukas
2   Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Thjon J. Tang
3   Department of Gastroenterology and Hepatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands
,
Paul Didden
1   Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Bas P. L. Wijnhoven
4   Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Marco J. Bruno
1   Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
,
Arjun D. Koch
1   Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

submitted 07 November 2016

accepted after revision 08 May 2017

Publication Date:
21 June 2017 (online)

Abstract

Background and study aims Treatment strategies for clinical (c)T2N0M0 esophageal adenocarcinoma (EAC) are subject to debate owing to the relative inaccuracy of tumor staging by endoscopic ultrasound (EUS), with profound implications in overstaged patients. We aimed to evaluate the final histological diagnosis of patients initially staged as having a cT2 tumor by EUS, and to assess the value of endoscopic reassessment by an interventional endoscopist, followed by an endoscopic resection when deemed feasible.

Patients and methods Two distinct cohorts of patients with cT2 EAC as determined by EUS were included: a retrospective surgical cohort of patients treated by primary esophagectomy, and a prospective cohort of patients who underwent an endoscopic reassessment by an interventional endoscopist. The main outcome measure was the final pathological (p)T stage.

Results We identified 134 patients with stage T2 EAC from the surgical cohort. In 72 patients treated by primary esophagectomy, 32/72 (44 %) were downstaged to a pT1 tumor. In 12/72 (17 %), the surgical resection specimen showed tumor characteristics that fulfilled the current criteria for a curative endoscopic resection. In 13 prospectively identified patients with cT2N0M0 EAC, an expert endoscopic reassessment was done. In 11/13 (85 %) the lesion appeared endoscopically resectable and a complete endoscopic resection was performed. Histology revealed a pT1 tumor in all 11 patients, with 5/13 (38 %) fulfilling current criteria for a curative endoscopic resection.

Conclusions In this study, 44 % of cT2 EACs were in fact pT1 tumors. Curative treatment by endoscopic resection was achieved in more than a third of these cases. To avoid an unnecessary esophagectomy, an endoscopic reassessment by an interventional endoscopist is recommended for all patients with cT2N0M0 EAC.

 
  • References

  • 1 Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
  • 2 Pennathur A, Gibson MK, Jobe BA. et al. Oesophageal carcinoma. Lancet 2013; 381: 400-412
  • 3 Hardacker TJ, Ceppa D, Okereke I. et al. Treatment of clinical T2N0M0 esophageal cancer. Ann Surg Oncol 2014; 21: 3739-3743
  • 4 Speicher PJ, Ganapathi AM, Englum BR. et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. J Thorac Oncol 2014; 9: 1195-1201
  • 5 Vallbohmer D, Sisic L, Blank S. et al. Clinically staged cT2 adenocarcinomas of the gastroesophageal junction: accuracy of staging and therapeutic consequences. Oncol Res Treat 2014; 37: 97-104
  • 6 Crabtree TD, Kosinski AS, Puri V. et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg 2013; 96: 382-390
  • 7 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut 2014; 63: 7-42
  • 8 Spechler SJ, Sharma P, Souza RF. et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140: e18-e52
  • 9 Evans JA, Early DS, Chandraskhara V. et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointestinal Endoscopy 2013; 77: 328-334
  • 10 van Hagen P, Hulshof MCCM, van Lanschot JJB. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. NEJM 2012; 366: 2074-2084
  • 11 Khanna LG, Gress FG. Preoperative evaluation of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29: 179-191
  • 12 Didden P, Spaander MCW, Wijnhoven BPL. et al. Improving the quality of pretreatment staging in patients with esophageal carcinoma – a fast track study. Acta Oncologica 2012; 51: 362-367
  • 13 O’Farrell N, Malik V, Donohoe C. et al. Appraisal of Staging Endoscopic Ultrasonography in a Modern High-Volume Esophageal Program. World J Surg 2013; 37: 1666-1672
  • 14 Pech O, Günter E, Dusemund F. et al. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010; 42: 456-461
  • 15 Zhang JQ, Hooker CM, Brock MV. et al. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg 2012; 93: 429-435 ; discussion 436–427
  • 16 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc; 2003 58. S3-S43
  • 17 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016; 111: 30-50 , quiz 51
  • 18 Fotis D, Doukas M, Wijnhoven BPL. et al. Submucosal invasion and risk of lymph node invasion in early Barrett’s cancer; potential impact of different classification systems on patient management. United European Gastroenterol J 2015; 3: 505-513
  • 19 Boys JA, Worrell SG, Chandrasoma P. et al. Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study. J Gastrointest Surg 2016; 20: 6-12 ; discussion 12
  • 20 Manner H, Pech O, Heldmann Y. et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc 2015; 29: 1888-1896
  • 21 Sepesi B, Watson TJ, Zhou D. et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210: 418-427
  • 22 Alvarez Herrero L, Pouw RE, van Vilsteren FG. et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42: 1030-1036
  • 23 Choi J, Kim SG, Kim JS. et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010; 24: 1380-1386
  • 24 Puli SR, Reddy JB, Bechtold ML. et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490
  • 25 Rice TW, Mason DP, Murthy SC. et al. T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg 2007; 133: 317-324
  • 26 Lee L, Ronellenfitsch U, Hofstetter WL. et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg 2013; 217: 191-199
  • 27 Leers JM, DeMeester SR, Oezcelik A. et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011; 253: 271-278
  • 28 Alvarez Herrero L, Pouw RE, van Vilsteren FG. et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endoscopy 2011; 43: 177-183
  • 29 Pech O, May A, Manner H. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660 .e651
  • 30 Pouw RE, Peters FP, Sempoux C. et al. Stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia: report on a Brussels' cohort. Endoscopy 2008; 40: 892-898
  • 31 Terheggen G, Horn EM, Vieth M. et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia. Gut 2017; 66: 783-793
  • 32 Komeda Y, Bruno M, Koch A. EMR is not inferior to ESD for early Barrett’s and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates. Endosc Int Open 2014; 2: E58-E64
  • 33 Metzger R, Bollschweiler E, Vallbohmer D. et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?. Dis Esophagus 2004; 17: 310-314
  • 34 May A, Gunter E, Roth F. et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53: 634-640
  • 35 Pouw RE, Heldoorn N, Alvarez Herrero L. et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73: 662-668